High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients

Correlation with clonal cytogenetic evolution but not response to therapy

Stephanie G. Willis, Thoralf Lange, Shadmehr Demehri, Sandra Otto, Lucy Crossman, Dietger Niederwieser, Eric P. Stoffregen, Shannon McWeeney, Ines Kovacs, Byung Park, Brian Druker, Michael W. Deininger

Research output: Contribution to journalArticle

266 Citations (Scopus)

Abstract

Mutations in the kinase domain (KD) of BCR-ABL are the leading cause of acquired imatinib resistance. In some cases, identical mutations were detected at relapse and in pretherapeutic specimens, consistent with selection of resistant clones in the presence of drug. However, the incidence of KD mutations in imatinib-naive patients, irrespective of response to therapy, is unknown. We studied mutation frequency in 66 patients with chronic myelogenous leukemia (CML), using cDNA sequencing and allele-specific oligonucleotide-polymerase chain reaction (ASO-PCR) assays for 8 common mutations. Thirteen patients were positive by ASO-PCR only, 1 by ASO-PCR and sequencing, and 1 by sequencing only (overall frequency, 22.7%). T315I was most frequent (12% of patients). Eleven of the 14 patients with positive ASO-PCR had follow-up samples available for sequencing. Wild-type sequence was detected in 6 of 11, 2 different mutations in 1 of 11, and identical mutations in 4 of 11 patients, 2 of whom had achieved major cytogenetic response. In multivariate analysis mutation detection was associated with clonal cytogenetic evolution, exposure to 6-Thioguanine, and a low platelet count, but not with response to imatinib, event-free survival, and overall survival. KD mutants present at low levels do not invariably lead to relapse, and additional factors are required to induce a fully drug-resistant phenotype.

Original languageEnglish (US)
Pages (from-to)2128-2137
Number of pages10
JournalBlood
Volume106
Issue number6
DOIs
StatePublished - Sep 15 2005

Fingerprint

Clonal Evolution
Polymerase chain reaction
Cytogenetics
Phosphotransferases
Mutation
Alleles
Polymerase Chain Reaction
Thioguanine
Therapeutics
Platelets
Pharmaceutical Preparations
Assays
Complementary DNA
Recurrence
Mutation Rate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib Mesylate
ribonucleotide polymerase
Platelet Count
Disease-Free Survival

ASJC Scopus subject areas

  • Hematology

Cite this

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients : Correlation with clonal cytogenetic evolution but not response to therapy. / Willis, Stephanie G.; Lange, Thoralf; Demehri, Shadmehr; Otto, Sandra; Crossman, Lucy; Niederwieser, Dietger; Stoffregen, Eric P.; McWeeney, Shannon; Kovacs, Ines; Park, Byung; Druker, Brian; Deininger, Michael W.

In: Blood, Vol. 106, No. 6, 15.09.2005, p. 2128-2137.

Research output: Contribution to journalArticle

Willis, Stephanie G. ; Lange, Thoralf ; Demehri, Shadmehr ; Otto, Sandra ; Crossman, Lucy ; Niederwieser, Dietger ; Stoffregen, Eric P. ; McWeeney, Shannon ; Kovacs, Ines ; Park, Byung ; Druker, Brian ; Deininger, Michael W. / High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients : Correlation with clonal cytogenetic evolution but not response to therapy. In: Blood. 2005 ; Vol. 106, No. 6. pp. 2128-2137.
@article{0879839f5b8147969244904a2acb0641,
title = "High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: Correlation with clonal cytogenetic evolution but not response to therapy",
abstract = "Mutations in the kinase domain (KD) of BCR-ABL are the leading cause of acquired imatinib resistance. In some cases, identical mutations were detected at relapse and in pretherapeutic specimens, consistent with selection of resistant clones in the presence of drug. However, the incidence of KD mutations in imatinib-naive patients, irrespective of response to therapy, is unknown. We studied mutation frequency in 66 patients with chronic myelogenous leukemia (CML), using cDNA sequencing and allele-specific oligonucleotide-polymerase chain reaction (ASO-PCR) assays for 8 common mutations. Thirteen patients were positive by ASO-PCR only, 1 by ASO-PCR and sequencing, and 1 by sequencing only (overall frequency, 22.7{\%}). T315I was most frequent (12{\%} of patients). Eleven of the 14 patients with positive ASO-PCR had follow-up samples available for sequencing. Wild-type sequence was detected in 6 of 11, 2 different mutations in 1 of 11, and identical mutations in 4 of 11 patients, 2 of whom had achieved major cytogenetic response. In multivariate analysis mutation detection was associated with clonal cytogenetic evolution, exposure to 6-Thioguanine, and a low platelet count, but not with response to imatinib, event-free survival, and overall survival. KD mutants present at low levels do not invariably lead to relapse, and additional factors are required to induce a fully drug-resistant phenotype.",
author = "Willis, {Stephanie G.} and Thoralf Lange and Shadmehr Demehri and Sandra Otto and Lucy Crossman and Dietger Niederwieser and Stoffregen, {Eric P.} and Shannon McWeeney and Ines Kovacs and Byung Park and Brian Druker and Deininger, {Michael W.}",
year = "2005",
month = "9",
day = "15",
doi = "10.1182/blood-2005-03-1036",
language = "English (US)",
volume = "106",
pages = "2128--2137",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients

T2 - Correlation with clonal cytogenetic evolution but not response to therapy

AU - Willis, Stephanie G.

AU - Lange, Thoralf

AU - Demehri, Shadmehr

AU - Otto, Sandra

AU - Crossman, Lucy

AU - Niederwieser, Dietger

AU - Stoffregen, Eric P.

AU - McWeeney, Shannon

AU - Kovacs, Ines

AU - Park, Byung

AU - Druker, Brian

AU - Deininger, Michael W.

PY - 2005/9/15

Y1 - 2005/9/15

N2 - Mutations in the kinase domain (KD) of BCR-ABL are the leading cause of acquired imatinib resistance. In some cases, identical mutations were detected at relapse and in pretherapeutic specimens, consistent with selection of resistant clones in the presence of drug. However, the incidence of KD mutations in imatinib-naive patients, irrespective of response to therapy, is unknown. We studied mutation frequency in 66 patients with chronic myelogenous leukemia (CML), using cDNA sequencing and allele-specific oligonucleotide-polymerase chain reaction (ASO-PCR) assays for 8 common mutations. Thirteen patients were positive by ASO-PCR only, 1 by ASO-PCR and sequencing, and 1 by sequencing only (overall frequency, 22.7%). T315I was most frequent (12% of patients). Eleven of the 14 patients with positive ASO-PCR had follow-up samples available for sequencing. Wild-type sequence was detected in 6 of 11, 2 different mutations in 1 of 11, and identical mutations in 4 of 11 patients, 2 of whom had achieved major cytogenetic response. In multivariate analysis mutation detection was associated with clonal cytogenetic evolution, exposure to 6-Thioguanine, and a low platelet count, but not with response to imatinib, event-free survival, and overall survival. KD mutants present at low levels do not invariably lead to relapse, and additional factors are required to induce a fully drug-resistant phenotype.

AB - Mutations in the kinase domain (KD) of BCR-ABL are the leading cause of acquired imatinib resistance. In some cases, identical mutations were detected at relapse and in pretherapeutic specimens, consistent with selection of resistant clones in the presence of drug. However, the incidence of KD mutations in imatinib-naive patients, irrespective of response to therapy, is unknown. We studied mutation frequency in 66 patients with chronic myelogenous leukemia (CML), using cDNA sequencing and allele-specific oligonucleotide-polymerase chain reaction (ASO-PCR) assays for 8 common mutations. Thirteen patients were positive by ASO-PCR only, 1 by ASO-PCR and sequencing, and 1 by sequencing only (overall frequency, 22.7%). T315I was most frequent (12% of patients). Eleven of the 14 patients with positive ASO-PCR had follow-up samples available for sequencing. Wild-type sequence was detected in 6 of 11, 2 different mutations in 1 of 11, and identical mutations in 4 of 11 patients, 2 of whom had achieved major cytogenetic response. In multivariate analysis mutation detection was associated with clonal cytogenetic evolution, exposure to 6-Thioguanine, and a low platelet count, but not with response to imatinib, event-free survival, and overall survival. KD mutants present at low levels do not invariably lead to relapse, and additional factors are required to induce a fully drug-resistant phenotype.

UR - http://www.scopus.com/inward/record.url?scp=24744443720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24744443720&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-03-1036

DO - 10.1182/blood-2005-03-1036

M3 - Article

VL - 106

SP - 2128

EP - 2137

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -